Subjects n | 25 | 10 |
Baseline demographics |
Age years | 64.0 (53.0–75.0) | 35.0 (22.5–44.0) |
Sex |
Female | 7 (28.0) | 8 (80.0) |
Male | 18 (72.0) | 2 (20.0) |
BMI kg·m−2 | 28.50 (25.70–31.40) | 23.86 (22.77–25.89) |
Smoking history |
Current smoker | 1 (4.0) | 0 |
Ex-smoker | 9 (36.0) | 1 (10.0) |
Patients with COVID-19 (n=25) |
Baseline clinical variables |
FiO2 at proning | 0.32 (0.28–0.36) | |
ABG | n=10 | |
pH | 7.43 (7.40–7.47) | |
PaO2 kPa | 8.00 (7.83–9.03) | |
PaCO2 kPa | 4.50 (3.98–4.60) | |
Lactate mmol·L−1 | 1.70 (1.50–2.10) | |
FiO2 | 0.28 (0.22–0.33) | |
Inflammatory markers | n=25 | |
WCC (109·L−1) | 7.90 (6.00–11.10) | |
CRP mg·L−1 | 77.00 (40.00–141.00) | |
COVID-19 status |
SARS-CoV-2 PCR positive | n=25 | |
Symptom onset to admission (days) | 9.0 (3.0–11.0) | |
Admission to prone (days) | 2.0 (1.0–3.0) | |
Radiographic severity score | 5 (4–7) | |
COVID-19 therapeutic regimen |
Dexamethasone only | 10 (40.0) | |
Dexamethasone+Baricitinib | 2 (8.0) | |
Dexamethasone+Dapagliflozin+Ambrisentan | 3 (12.0) | |
Dexamethasone+EDP1815# | 1 (4.0) | |
Dexamethasone+Ravulizumab | 2 (8.0) | |
Dexamethasone+Remdesivir | 4 (16.0) | |
Dexamethasone+Tocilizumab | 1 (4.0) | |
Comorbidities |
Respiratory |
Asthma | 5 (20.0) | |
COPD | 2 (8.0) | |
Interstitial lung disease | 1 (4.0) | |
Pulmonary tuberculosis | 1 (4.0) | |
Cardiovascular |
Atrial fibrillation | 2 (8.0) | |
Dilated cardiomyopathy | 1 (4.0) | |
Hypercholesterolaemia | 1 (4.0) | |
Hypertension | 8 (32.0) | |
Ischaemic heart disease | 3 (12.0) | |
Peripheral vascular disease | 1 (4.0) | |
Other significant |
Connective tissue disease | 2 (8.0) | |
Chronic kidney disease | 2 (8.0) | |
Haematological malignancy | 1 (4.0) | |
Hypothyroidism | 2 (8.0) | |
Osteoarthritis | 2 (8.0) | |
Polymyalgia rheumatica | 2 (8.0) | |
Raynaud's disease | 1 (4.0) | |
Rheumatoid arthritis | 1 (4.0) | |
Type II diabetes mellitus | 4 (16.0) | |
Outcomes |
Death | 1 (4.0) | |
Intubation and ventilation | 1 (4.0) | |
Noninvasive ventilation | 1 (4.0) | |
Discharge | 24 (96) | |
Time from proning to discharge (days) | 7 (4–10.5) | |